Published in J Clin Oncol on October 15, 2002
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res (2009) 1.47
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res (2010) 1.40
FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med (2012) 1.32
Tumor metabolism and perfusion in head and neck squamous cell carcinoma: pretreatment multimodality imaging with 1H magnetic resonance spectroscopy, dynamic contrast-enhanced MRI, and [18F]FDG-PET. Int J Radiat Oncol Biol Phys (2011) 1.26
Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol (2009) 1.25
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.15
Functional imaging of head and neck squamous cell carcinoma with diffusion-weighted MRI and FDG PET/CT: quantitative analysis of ADC and SUV. Eur J Nucl Med Mol Imaging (2013) 1.12
Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg (2005) 1.05
FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol (2008) 1.02
FDG-PET/CT pitfalls in oncological head and neck imaging. Insights Imaging (2014) 1.00
Head and neck squamous cell carcinoma: usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect. Eur Radiol (2008) 0.99
18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology (2009) 0.98
(18)F-FDG PET/CT surveillance at 3-6 and 12 months for detection of recurrence and second primary cancer in patients with head and neck squamous cell carcinoma. Br J Cancer (2013) 0.91
FDG-PET/CT as prognostic factor and surveillance tool for postoperative radiation recurrence in locally advanced head and neck cancer. Radiat Oncol J (2011) 0.91
PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging (2007) 0.90
18F-FDG PET/CT-based gross tumor volume definition for radiotherapy in head and neck cancer: a correlation study between suitable uptake value threshold and tumor parameters. Radiat Oncol (2010) 0.90
Preoperative [18F]-fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes may aid in selecting patients with oral cavity squamous cell carcinoma for salvage therapy after relapse. Eur J Nucl Med Mol Imaging (2009) 0.89
Common patterns of perineural spread in head-neck squamous cell carcinoma identified on fluoro-deoxy-glucose positron emission tomography/computed tomography. Indian J Nucl Med (2016) 0.87
Early detection of recurrent disease by FDG-PET/CT leads to management changes in patients with squamous cell cancer of the head and neck. Oncologist (2013) 0.87
An assessment of estimation methods for generalized linear mixed models with binary outcomes. Stat Med (2013) 0.87
2-Deoxy-2[F-18]FDG-PET for detection of recurrent laryngeal carcinoma after radiotherapy: interobserver variability in reporting. Mol Imaging Biol (2008) 0.85
Comparison between PET and PET/CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol (2007) 0.85
Positron emission tomography in pediatric radiation oncology: integration in the treatment-planning process. Pediatr Radiol (2004) 0.85
Improving imaging diagnosis of persistent nodal metastases after definitive therapy for oropharyngeal carcinoma: specific signs for CT and best performance of combined criteria. AJNR Am J Neuroradiol (2013) 0.84
Diagnostic modalities for distant metastasis in head and neck squamous cell carcinoma: are we changing life expectancy? Laryngoscope (2012) 0.84
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting locally residual or recurrent nasopharyngeal carcinoma: comparison with magnetic resonance imaging. Eur J Nucl Med Mol Imaging (2006) 0.84
PET in face and neck tumours. Cancer Imaging (2006) 0.83
Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2013) 0.81
Correlation of tissue biopsy and fine needle aspiration cytology with positron emission tomography results. Patholog Res Int (2011) 0.81
FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma. AJR Am J Roentgenol (2014) 0.81
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol (2012) 0.81
Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma. Ann Surg Oncol (2011) 0.80
Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2015) 0.79
PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging (2011) 0.77
Physiologic [18F]fluorodeoxyglucose uptake of floor of mouth muscles in PET/CT imaging: a problem of body position during FDG uptake? Cancer Imaging (2013) 0.77
Prognostic Value of Metabolic Activity Measured by (18)F-FDG PET/CT in Patients with Advanced Endometrial Cancer. Nucl Med Mol Imaging (2013) 0.77
The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer: A Cross-Sectional Analysis in Single Institute. Medicine (Baltimore) (2015) 0.77
Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment. Eur J Nucl Med Mol Imaging (2014) 0.76
18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence. Eur J Nucl Med Mol Imaging (2010) 0.76
PET/CT Is Complementary to Fine-Needle Aspiration Cytology in Assessment of Irradiated Neck in Head and Neck Cancers. Surg Res Pract (2014) 0.76
(18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. Eur J Nucl Med Mol Imaging (2016) 0.76
Role of dual time fluorodeoxyglucose (FDG) positron emission tomography-computed tomography in identifying co-existing inflammatory and malignant disease: Who holds it (FDG) longer? Indian J Nucl Med (2015) 0.75
Newer imaging techniques in head and neck cancer. Indian J Surg Oncol (2010) 0.75
Positron emission tomography-CT prediction of occult nodal metastasis in recurrent laryngeal cancer. Head Neck (2017) 0.75
An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study. Br J Radiol (2016) 0.75
Mixtures of receiver operating characteristic curves. Acad Radiol (2013) 0.75
Multimodality functional imaging using DW-MRI and (18)F-FDG-PET/CT during radiation therapy for human papillomavirus negative head and neck squamous cell carcinoma: Meixoeiro Hospital of Vigo Experience. World J Radiol (2017) 0.75
Laryngeal squamous cell cancer with late presentation of isolated liver metastasis on fluorodeoxyglucose positron emission tomography-computed tomography. Indian J Nucl Med (2016) 0.75
Combined SPECT/CT imaging using 123I-IMT in the detection of recurrent or persistent head and neck cancer. Eur Radiol (2005) 0.75
Role of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in the Evaluation of Head and Neck Carcinoma. World J Nucl Med (2017) 0.75
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg (2001) 5.94
Radiometric detection of the metabolic activity of Mycobacterium tuberculosis. J Nucl Med (1975) 5.30
Automated detection of Haemophilus influenzae. Appl Microbiol (1973) 3.16
Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2001) 3.06
Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol (1999) 2.97
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer (1997) 2.81
Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res (1998) 2.55
A new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index. Clin Cancer Res (1998) 2.43
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res (1999) 2.40
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol (2000) 2.39
Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol (1999) 2.38
Epiphora: treatment by means of dacryocystoplasty with balloon dilation of the nasolacrimal drainage apparatus. Radiology (1990) 2.21
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Prognostic significance of lymph node dissection in the treatment of malignant melanoma. Cancer (1970) 2.08
American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol (1999) 2.03
Imaging transgene expression with radionuclide imaging technologies. Neoplasia (2000) 2.03
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Human herpesvirus-6 associated with fatal haemophagocytic syndrome. Lancet (1990) 1.99
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med (1999) 1.95
Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery (1999) 1.94
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab (1999) 1.90
Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab (2000) 1.85
Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck (1996) 1.82
Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation (1999) 1.80
Angiosarcoma of the head and neck. Am J Surg (1994) 1.78
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases. Br J Cancer (2004) 1.75
Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med (2000) 1.74
Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys (2004) 1.74
Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg (1997) 1.71
Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue. Head Neck (1997) 1.71
Quantitative imaging of iodine-124 with PET. J Nucl Med (1996) 1.69
Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg (1993) 1.69
Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med (1998) 1.67
Chondrosarcomas of the head and neck. World J Surg (1993) 1.65
Outcomes in patients with poorly differentiated thyroid carcinoma. J Clin Endocrinol Metab (2014) 1.65
Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg (1996) 1.65
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol (2003) 1.63
Molecular cytogenetic characterization of head and neck squamous cell carcinoma and refinement of 3q amplification. Cancer Res (2001) 1.62
Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol (1996) 1.61
Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid (2000) 1.59
Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab (2000) 1.59
Immunomodulation treatment for childhood virus-associated haemophagocytic lymphohistiocytosis. Br J Haematol (1995) 1.56
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol (1998) 1.56
Genetic analysis as an aid in diagnosis for patients with midline carcinomas of uncertain histologies. J Natl Cancer Inst (1991) 1.55
Phase and amplitude binning for 4D-CT imaging. Phys Med Biol (2007) 1.52
American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol (1999) 1.52
Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J Nucl Med (1966) 1.49
FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med (2001) 1.49
Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys (2002) 1.48
Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol (2010) 1.46
Prevalence and predictors of continued tobacco use after treatment of patients with head and neck cancer. Cancer (1995) 1.45
Low-risk differentiated thyroid cancer: the need for selective treatment. Ann Surg Oncol (1997) 1.44
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med (1989) 1.43
Intermediate-risk group for differentiated carcinoma of thyroid. Surgery (1994) 1.42
Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest (1983) 1.42
Hypopharyngeal cancer patient care evaluation. Laryngoscope (1997) 1.42
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol (1988) 1.41
Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol (1994) 1.41
Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med (1997) 1.41
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg (1999) 1.41
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med (1990) 1.41
Factors associated with complications in microvascular reconstruction of head and neck defects. Plast Reconstr Surg (1999) 1.40
Impact of clinicopathologic parameters on patient survival in carcinoma of the cervical esophagus. Am J Surg (1995) 1.40
Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology (2001) 1.40
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Small cell neuroendocrine carcinoma of the nasal cavity and paranasal sinuses. Hum Pathol (1998) 1.38
Hürthle cell carcinoma: a critical histopathologic appraisal. J Clin Oncol (2001) 1.37
Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: a report from the Taiwan Pediatric Oncology Group (TPOG) Acta Paediatr Taiwan (2000) 1.37
Basaloid squamous cell carcinoma of the head and neck. Laryngoscope (2000) 1.36
Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg (1995) 1.36
Quantitative bone metastases analysis based on image segmentation. J Nucl Med (1997) 1.36
Squamous cell carcinoma of the tongue in young patients: a matched-pair analysis. Head Neck (1998) 1.35
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep (1984) 1.35
Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys (2004) 1.35
3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol (1998) 1.35
Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem (2001) 1.35
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
Dimensions of the normal adult spleen scan and prediction of spleen weight. J Nucl Med (1971) 1.33
Hamartomas of the lung. Surg Gynecol Obstet (1973) 1.33
Alloimmunization following blood transfusion. Arch Pathol Lab Med (1989) 1.30
Papillary carcinoma of the thyroid. Recurrence in the thyroid gland after initial surgical treatment. Am J Surg (1972) 1.30
Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck (1990) 1.30
Long interspersed repeated DNA (LINE) causes polymorphism at the rat insulin 1 locus. Mol Cell Biol (1985) 1.29
Ectopia cordis and other midline defects. Ann Thorac Surg (2000) 1.28
Critical assessment of supraomohyoid neck dissection. Am J Surg (1988) 1.27
Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg (1985) 1.27
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res (2001) 1.26
Midazolam changes cerebral blood flow in discrete brain regions: an H2(15)O positron emission tomography study. Anesthesiology (1997) 1.25
Dermatofibrosarcoma protuberans of the head and neck. Ann Surg Oncol (2000) 1.25